DOCSLIB.ORG

Guidelines on Urological Infections

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Guidelines on Urological Infections M. Grabe (Chairman), T.E. Bjerklund-Johansen, H. Botto, M. Çek, K.G. Naber, P. Tenke, F. Wagenlehner © European Association of Urology 2010 TABLE OF CONTENTS PAGE 1. INTRODUCTION 7 1.1 Pathogenesis of urinary tract infections 7 1.2 Microbiological and other laboratory findings 7 1.3 Classification of urological infections 8 1.4 Aim of guidelines 8 1.5 Methods 9 1.6 Level of evidence and grade of guideline recommendations 9 1.7 References 9 2. UNCOMPLICATED URINARY TRACT INFECTIONS IN ADULTS 11 2.1 Definition 11 2.1.1 Aetiological spectrum 11 2.2 Acute uncomplicated cystitis in premenopausal, non-pregnant women 11 2.2.1 Diagnosis 11 2.2.1.1 Clinical diagnosis 11 2.2.1.2 Laboratory diagnosis 11 2.2.2 Therapy 11 2.2.3 Follow up 12 2.3 Acute uncomplicated pyelonephritis in premenopausal, non-pregnant women 12 2.3.1 Diagnosis 12 2.3.1.1 Clinical diagnosis 12 2.3.1.2 Laboratory diagnosis 12 2.3.1.3 Imaging diagnosis 13 2.3.2 Therapy 13 2.3.2.1 Mild and moderate cases of acute uncomplicated pyelonephritis 13 2.3.2.2 Severe cases of acute uncomplicated pyelonephritis 13 2.3.3 Follow-up 14 2.4 Recurrent (uncomplicated) UTIs in women 16 2.4.1 Diagnosis 16 2.4.2 Prevention 16 2.4.2.1 Antimicrobial prophylaxis 16 2.4.2.2 Immunoactive prophylaxis 16 2.4.2.3 Prophylaxis with probiotics 17 2.4.2.4 Prophylaxis with cranberry 17 2.5 Urinary tract infections in pregnancy 17 2.5.1 Definition of significant bacteriuria 17 2.5.2 Screening 17 2.5.3 Treatment of asymptomatic bacteriuria 17 2.5.4 Duration of therapy 18 2.5.5 Follow-up 18 2.5.6 Prophylaxis 18 2.5.7 Treatment of pyelonephritis 18 2.5.8 Complicated UTI 18 2.6 UTIs in postmenopausal women 18 2.6.1 Risk factors 18 2.6.2 Diagnosis 18 2.6.3 Treatment 18 2.7 Acute uncomplicated UTIs in young men 19 2.7.1 Men with acute uncomplicated UTI 19 2.7.2 Men with UTI and concomitant prostate infection 19 2.8 Asymptomatic bacteriuria 19 2.8.1 Diagnosis 19 2.8.2 Screening 19 2.9 References 26 3. URINARY TRACT INFECTIONS IN CHILDREN 34 3.1 Summary and recommendations 34 3.2 Background 34 2 UPDATE APRIL 2010 3.3 Aetiology 34 3.4 Pathogenesis and risk factors 35 3.5 Signs and symptoms 35 3.6 Classification 35 3.6.1 Severe UTI 36 3.6.2 Simple UTI 36 3.7 Diagnosis 36 3.7.1 Physical examination 36 3.7.2 Laboratory tests 36 3.7.2.1 Collection of urine 36 3.7.2.1.1 Suprapubic bladder aspiration 36 3.7.2.1.2 Bladder catheterization 36 3.7.2.1.3 Plastic bag attached to the genitalia 36 3.7.2.2 Quantification of bacteriuria 36 3.7.2.3 Other biochemical markers 36 3.7.2.3.1 Nitrite 37 3.7.2.3.2 Leucocyte esterase 37 3.7.2.3.3 C-reactive protein 37 3.7.2.3.4 Urinary N-acetyl-ß-glucosaminidase 37 3.7.2.3.5 Interleukin-6 37 3.7.3 Imaging of the urinary tract 38 3.7.3.1 Ultrasonography 38 3.7.3.2 Radionuclide studies 38 3.7.3.3 Cystourethrography 38 3.7.3.3.1 Conventional voiding cystourethrography 38 3.7.3.3.2 Radionuclide cystography (indirect) 38 3.7.3.3.3 Cystosonography 38 3.7.3.4 Additional imaging 38 3.7.3.5 Urodynamic evaluation 39 3.8 Schedule of investigation 39 3.9 Treatment 39 3.9.1 Severe UTIs 39 3.9.2 Simple UTIs 40 3.9.3 Prophylaxis 40 3.10 Acknowledgement 40 3.11 References 41 4. UTIs IN RENAL INSUFFICIENCY, TRANSPLANT RECIPIENTS, DIABETES MELLITUS 45 AND IMMUNOSUPRESSION 45 4.1 Summary 45 4.1.1 Acute effects of UTI on the kidney 45 4.1.2 Chronic renal disease and UTI 45 4.1.2.1 Adult polycystic kidney disease (APCKD) 45 4.1.2.2 Calculi and UTI 46 4.1.2.3 Obstruction and UTI 46 4.1.3 UTI in renal transplantation and immunosuppression 46 4.1.4 Antibiotic treatment for UTI in renal insufficiency and after renal transplantation 46 4.2 Background 46 4.3 Acute effects of a UTI on the kidney 46 4.3.1 Vesicoureteric and intrarenal reflux 46 4.3.2 Obstructive neuropathy 46 4.3.3 Renal effects of severe UTI 47 4.3.4 Acute effects of UTI on the normal kidney 47 4.3.5 Renal scarring 47 4.3.6 Specific conditions in which an acute UTI causes renal damage 48 4.3.6.1 Diabetes mellitus 48 4.3.6.2 Tuberculosis 49 4.4 Chronic renal disease and UTI 49 4.4.1 Adult dominant polycystic kidney disease (ADPK) 49 4.4.2 Renal calculi 49 UPDATE APRIL 2010 3 4.5 UTI in renal transplantation 49 4.5.1 Donor organ infection 50 4.5.2 Graft failure 50 4.5.3 Kidney and whole-organ pancreas transplantation 50 4.6 Antibiotic therapy in renal failure/transplantation 50 4.6.1 Treatment of UTI in renal transplant recipients 51 4.6.2 Fungal infections 52 4.6.3 Schistosomiasis 52 4.7 Immunosuppression 52 4.7.1 HIV infection 52 4.7.2 Viral and fungal infections 52 4.8 References 52 4.8.1 Further reading 56 5. COMPLICATED UTIs DUE TO UROLOGICAL DISORDERS 56 5.1 Summary and recommendations 56 5.2 Definitions and classification 56 5.2.1 Clinical presentation 57 5.2.2 Urine cultures 57 5.3 Microbiology 57 5.3.1 Spectrum and antibiotic resistance 57 5.3.2 Complicated UTIs associated with urinary stones 57 5.3.3 Complicated UTIs associated with urinary catheters 58 5.4 Treatment 58 5.4.1 General principles 58 5.4.2 Choice of antibiotics 58 5.4.3 Duration of antibiotic therapy 59 5.4.4 Complicated UTIs associated with urinary stones 59 5.4.5 Complicated UTIs associated with indwelling catheters 59 5.4.6 Complicated UTIs in spinal-cord injured patients 59 5.4.7 Follow-up after treatment 59 5.5 Conclusions 60 5.6 References 60 6. CATHETER-ASSOCIATED UTIs 61 6.1 Abstract 61 6.2 Summary of recommendations 62 6.3 Reference 63 7. SEPSIS IN UROLOGY (UROSEPSIS) 63 7.1 Summary and recommendations 63 7.2 Background 64 7.3 Definition and clinical manifestation of sepsis in urology 64 7.4 Physiology and biochemical markers 65 7.4.1 Cytokines as markers of the septic response 65 7.4.2 Procalcitonin is a potential marker of sepsis 65 7.5 Prevention 65 7.5.1 Preventive measures of proven or probable efficacy 65 7.5.2 Appropriate peri-operative antimicrobial prophylaxis 66 7.5.3 Preventive measures of debatable efficacy 66 7.5.4 Ineffective or counterproductive measures 66 7.6 Treatment 66 7.6.1 Relief of obstruction 66 7.6.2 Antimicrobial therapy 66 7.6.3 Adjunctive measures 66 7.7 Conclusion 67 7.8 Acknowledgement 67 7.9 References 67 4 UPDATE APRIL 2010 8. URETHRITIS 68 8.1 Definition 68 8.2 Epidemiology 68 8.3 Pathogens 68 8.4 Route of infection and pathogenesis 68 8.5 Clinical course 68 8.6 Diagnosis 69 8.7 Therapy 69 8.7.1 Treatment of gonorrhoeal urethritis 69 8.7.2 Treatment of non-gonorrhoeal urethritis 69 8.8 Follow-up and prevention 69 8.9 References 70 9. PROSTATITIS AND CHRONIC PELVIC PAIN SYNDROME 71 9.1 Summary and recommendations 71 9.2 Introduction and definition 71 9.3 Diagnosis 71 9.3.1 History and symptoms 71 9.3.1.1 Symptom questionnaires 72 9.3.2 Clinical findings 72 9.3.3 Urine cultures and expressed prostatic secretion 72 9.3.4 Perineal biopsy 73 9.3.5 Other tests 73 9.3.6 Classification systems 73 9.3.7 Diagnostic evaluation 74 9.3.8 Additional investigations 74 9.4 Treatment 75 9.4.1 Antibiotics 75 9.4.2 Antibiotics and α-blockers in combination therapy 75 9.4.3 Other oral medication 76 9.4.4 Intraprostatic injection of antibiotics 76 9.4.5 Surgery 76 9.4.6 Other treatment forms 76 9.5 References 76 10. EPIDIDYMITIS AND ORCHITIS 79 10.1 Definition and classification 79 10.2 Incidence and prevalence 80 10.3 Morbidity 80 10.4 Pathogenesis and pathology 80 10.5 Diagnosis 80 10.5.1 Differential diagnosis 80 10.6 Treatment 80 10.7 References 81 11. PERI-OPERATIVE ANTIBACTERIAL PROPHYLAXIS IN UROLOGY 81 11.1 Summary 81 11.2 Introduction 83 11.3 Goals of peri-operative antibacterial prophylaxis 83 11.4 Risk factors 84 11.5 Principles of antibiotic prophylaxis 84 11.5.1 Timing 85 11.5.2 Route of administration 85 11.5.3 Duration of the regimen 85 11.5.4 Choice of antibiotics 85 11.6 Prophylactic regimens in defined procedures 85 11.6.1 Diagnostic procedures 86 11.6.2 Endo-urological treatment procedures 86 11.6.3 Laparoscopic surgery 87 UPDATE APRIL 2010 5 11.6.4 Open or laparoscopic urological operations without opening of the urinary tract (clean procedures) 87 11.6.5 Open or laparoscopic urological operations with open urinary tract (clean- contaminated procedures) 87 11.6.6 Open urological operations with bowel segment (clean-contaminated or contaminated procedures) 87 11.6.7 Post-operative drainage of the urinary tract 87 11.6.8 Implantation of prosthetic devices 87 11.7 References 89 12.
Recommended publications
  • A Computational Drug Repositioning Case Study Prashant S. Kharkar1*, Ponnadurai Ramasami2, Yee S

    A Computational Drug Repositioning Case Study Prashant S. Kharkar1*, Ponnadurai Ramasami2, Yee S

    Electronic Supplementary Material (ESI) for RSC Advances. This journal is © The Royal Society of Chemistry 2016 Discovery of Anti-Ebola Drugs: A Computational Drug Repositioning Case Study Prashant S. Kharkar1*, Ponnadurai Ramasami2, Yee Siew Choong3, Lydia Rhyman2 and Sona Warrier1 1SPP School of Pharmacy and Technology Management, SVKM’s NMIMS, V. L. Mehta Road, Vile Parle (West), Mumbai-400 056. INDIA. 2 Computational Chemistry Group, Department of Chemistry, Faculty of Science, University of Mauritius, Réduit 80837, Mauritius 3Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Malaysia Contents Sr. No. Description Page No. 1 Table 1S 1 2 Figure 1S 28 3 Figure 2S 29 4 Figure 3S 30 5 Figure 4S 31 6 Figure 5S 32 Table 1S. Top hits (#100) identified from EON screening using query 1 Estimated Sr. EON_ Shape Free Energy Drug Structure ET_pb ET_coul ET_combo Rank No. Tanimoto of Binding (kcal/mol) OH O Br N O 1 1 S -9.88 HO O O O S O O 2 Sitaxentan S 0.633 0.914 0.926 0.294 1 -14.37 HN O Cl O N O HO 3 Alitretinoina 0.66 0.91 0.906 0.246 2 -3.91 NH 2 S N N O O HN 4 Ceftriaxone S 0.606 0.937 0.823 0.217 3 -12.33 N O S N O HO O N N O H O a 5 Acitretin O 0.637 0.936 0.809 0.172 4 -3.71 OH HO NH 2 HO N N 6 Cidofovir P O 0.473 0.633 0.783 0.31 5 -4.21 HO O O N N N N 7 Telmisartan 0.601 0.908 0.775 0.174 6 -6.46 OH O 8 Nateglinidea HN 0.54 0.874 0.745 0.205 7 -3.78 OH O O H N 2 S OH N O N S O 9 Ceftizoxime N 0.557 0.88 0.735 0.178 8 -11.35 H O N O OH O 10 Treprostinil OH 0.432 0.846 0.732 0.301 9 -3.41 O HO O O S
  • Medical Review(S) Clinical Review

    Medical Review(S) Clinical Review

    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 200327 Priority or Standard Standard Submit Date(s) December 29, 2009 Received Date(s) December 30, 2009 PDUFA Goal Date October 30, 2010 Division / Office Division of Anti-Infective and Ophthalmology Products Office of Antimicrobial Products Reviewer Name(s) Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD Review Completion October 29, 2010 Date Established Name Ceftaroline fosamil for injection (Proposed) Trade Name Teflaro Therapeutic Class Cephalosporin; ß-lactams Applicant Cerexa, Inc. Forest Laboratories, Inc. Formulation(s) 400 mg/vial and 600 mg/vial Intravenous Dosing Regimen 600 mg every 12 hours by IV infusion Indication(s) Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Community-acquired Bacterial Pneumonia (CABP) Intended Population(s) Adults ≥ 18 years of age Template Version: March 6, 2009 Reference ID: 2857265 Clinical Review Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD NDA 200327: Teflaro (ceftaroline fosamil) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 9 1.1 Recommendation on Regulatory Action ........................................................... 10 1.2 Risk Benefit Assessment.................................................................................. 10 1.3 Recommendations for Postmarketing Risk Evaluation and Mitigation Strategies ........................................................................................................................
  • Efficacy of Amoxicillin and Amoxicillin/Clavulanic Acid in the Prevention of Infection and Dry Socket After Third Molar Extraction

    Efficacy of Amoxicillin and Amoxicillin/Clavulanic Acid in the Prevention of Infection and Dry Socket After Third Molar Extraction

    Med Oral Patol Oral Cir Bucal. 2016 Jul 1;21 (4):e494-504. Amoxicillin in the prevention of infectious complications after tooth extraction Journal section: Oral Surgery doi:10.4317/medoral.21139 Publication Types: Review http://dx.doi.org/doi:10.4317/medoral.21139 Efficacy of amoxicillin and amoxicillin/clavulanic acid in the prevention of infection and dry socket after third molar extraction. A systematic review and meta-analysis María-Iciar Arteagoitia 1, Luis Barbier 2, Joseba Santamaría 3, Gorka Santamaría 4, Eva Ramos 5 1 MD, DDS, PhD, Associate Professor, Stomatology I Department, University of the Basque Country (UPV/EHU), BioCruces Health Research Institute, Spain; Consolidated research group (UPV/EHU IT821-13) 2 MD PhD, Chair Professor, Maxillofacial Surgery Department, BioCruces Health Research Institute, Cruces University Hos- pital, University of the Basque Country (UPV/EHU), Spain; Consolidated research group (UPV/EHU IT821-13) 3 MD, DDS, PhD, Professor and Chair, Maxillofacial Surgery Department, Bio Cruces Health Research Institute, Cruces University Hospital, University of the Basque Country (UPV/EHU), Bizkaia, Spain; Consolidated research group (UPV/EHU IT821-13) 4 DDS, PhD, Associate Professor, Stomatology I Department, University of the Basque Country (UPV/EHU), BioCruces Health Research Institute, Spain; Consolidated research group (UPV/EHU IT821-13) 5 PhD, Degree in Farmacy, BioCruces Health Research Institute, Cruces University Hospital. Spain Correspondence: Servicio Cirugía Maxilofacial Hospital Universitario de Cruces Plaza de Cruces s/n Arteagoitia MI, Barbier L, Santamaría J, Santamaría G, Ramos E. Ef- Barakaldo, Bizkaia, Spain ficacy of amoxicillin and amoxicillin/clavulanic acid in the prevention [email protected] of infection and dry socket after third molar extraction.
  • Antibiotic Resistance and Molecular Typing of Pseudomonas Aeruginosa: Focus on Imipenem

    Antibiotic Resistance and Molecular Typing of Pseudomonas Aeruginosa: Focus on Imipenem

    BJID 2002; 6 (February) 1 Antibiotic Resistance and Molecular Typing of Pseudomonas aeruginosa: Focus on Imipenem Ana Lúcia Peixoto de Freitas and Afonso Luis Barth Federal University of Rio Grande do Sul, Pharmacy School, Clinical Hospital of Porto Alegre, Cardiology Institute, Porto Alegre, RS; Catholic University of Pelotas, Pharmacy School, Pelotas, RS, Brazil Susceptibility tests by disk diffusion and by E-test and molecular typing by macrorestriction analysis were performed to determine the relatedness of Pseudomonas aeruginosa isolates from three distinct hospitals. The resistance profile of 124 isolates to 8 antimicrobial agents was determined in three different hospitals, in Porto Alegre, Brazil. Frequencies of susceptibility ranged from 43.9% for carbenicillin to 87.7% for ceftazidime. Cross-resistance data of imipenem-resistant isolates indicated that most (70%) were also resistant to carbenicillin, although 30% remained susceptible to ceftazidime and cefepime. In general, susceptibility profiles were not able to determine relatedness among isolates of P. aeruginosa. On the other hand, molecular typing by macrorestriction analysis demonstrated high discriminatory power and identified 66 strains among 72 isolates of P. aeruginosa. Imipenem-susceptible isolates were all different. However, identical clones of imipenem-resistant isolates were found in two of the hospitals, despite variable response to other antibiotics. No clustering of infection among the different medical centers was observed. In conclusion, clones of P. aeruginosa did not spread among the different hospitals in our city even though related isolates of imipenem- resistant P. aeruginosa were found. Key Words: Pseudomonas aeruginosa, antibiotic resistance, imipenem. Despite improvements in antibiotic therapy, However, nosocomial isolates may easily develop Pseudomonas aeruginosa remains as one of the most resistance to carbapenens due to reduced uptake of prominent Gram-negative bacteria causing hospital- the drug, which leads to outbreaks of multiresistant/ associated infections.
  • Empiric Antimicrobial Therapy for Diabetic Foot Infection

    Empiric Antimicrobial Therapy for Diabetic Foot Infection

    Empiric Antimicrobial Therapy for Diabetic Foot Infection (NB Provincial Health Authorities Anti-Infective Stewardship Committee, September 2019) Infection Severity Preferred Empiric Regimens Alternative Regimens Comments Mild Wound less than 4 weeks duration:d Wound less than 4 weeks duration:e • Outpatient management • Cellulitis less than 2 cm and • cephalexin 500 – 1000 mg PO q6h*,a OR • clindamycin 300 – 450 mg PO q6h (only if recommended ,a • cefadroxil 500 – 1000 mg PO q12h* severe delayed reaction to a beta-lactam) without involvement of deeper • Tailor regimen based on culture tissues and susceptibility results and True immediate allergy to a beta-lactam at MRSA Suspected: • Non-limb threatening patient response risk of cross reactivity with cephalexin or • doxycycline 200 mg PO for 1 dose then • No signs of sepsis cefadroxil: 100 mg PO q12h OR • cefuroxime 500 mg PO q8–12h*,b • sulfamethoxazole+trimethoprim 800+160 mg to 1600+320 mg PO q12h*,f Wound greater than 4 weeks duration:d Wound greater than 4 weeks duratione • amoxicillin+clavulanate 875/125 mg PO and MRSA suspected: q12h*,c OR • doxycycline 200 mg PO for 1 dose then • cefuroxime 500 mg PO q8–12h*,b AND 100 mg PO q12h AND metroNIDAZOLE metroNIDAZOLE 500 mg PO q12h 500 mg PO q12h OR • sulfamethoxazole+trimethoprim 800+160 mg to 1600/320 mg PO q12h*,f AND metroNIDAZOLE 500 mg PO q12h Moderate Wound less than 4 weeks duration:d Wound less than 4 weeks duration:e • Initial management with • Cellulitis greater than 2 cm or • ceFAZolin 2 g IV q8h*,b OR • levoFLOXacin 750
  • Cefalexin in the WHO Essential Medicines List for Children Reject

    Cefalexin in the WHO Essential Medicines List for Children Reject

    Reviewer No. 1: checklist for application of: Cefalexin In the WHO Essential Medicines List for Children (1) Have all important studies that you are aware of been included? Yes No 9 (2) Is there adequate evidence of efficacy for the proposed use? Yes 9 No (3) Is there evidence of efficacy in diverse settings and/or populations? Yes 9 No (4) Are there adverse effects of concern? Yes 9 No (5) Are there special requirements or training needed for safe/effective use? Yes No 9 (6) Is this product needed to meet the majority health needs of the population? Yes No 9 (7) Is the proposed dosage form registered by a stringent regulatory authority? Yes 9 No (8) What action do you propose for the Committee to take? Reject the application for inclusion of the following presentations of cefalexin: • Tablets/ capsules 250mg • Oral suspensions 125mg/5ml and 125mg/ml (9) Additional comment, if any. In order to identify any additional literature, the following broad and sensitive search was conducted using the PubMed Clinical Query application: (cephalexin OR cefalexin AND - 1 - pediatr*) AND ((clinical[Title/Abstract] AND trial[Title/Abstract]) OR clinical trials[MeSH Terms] OR clinical trial[Publication Type] OR random*[Title/Abstract] OR random allocation[MeSH Terms] OR therapeutic use[MeSH Subheading]) Only one small additional study was identified, which looked at the provision of prophylactic antibiotics in patients presenting to an urban children's hospital with trauma to the distal fingertip, requiring repair.1 In a prospective randomised control trial, 146 patients were enrolled, of which 69 were randomised to the no-antibiotic group, and 66 were randomised to the antibiotic (cefalexin) group.

  • 28912 Oxoid FDA Cartridge Tables:1

    * Adapted in part from CLSI document M100-S23 (M02-A11) : “Disc diffusion supplemental tablesʼʼ Performance standards for antimicrobial susceptibility testing. The complete standard may be obtained from the Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, PA 19807. Test Cultures (zone diameters in mm) Antimicrobial Agent Disc Code Potency Resistant Intermediate Susceptible Amikacin AK 30 μg EnterobacteriaceaeK, P. aeruginosa, Acinetobacter spp., and Staphylococcus spp. ≤14 15-16 ≥17 Amoxycillin - Clavulanic Acid AMC 20/10 μg EnterobacteriaceaeE ≤13 14-17 ≥18 Staphylococcus spp.A,Q ≤19 — ≥20 Haemophilus spp.A,Y ≤19 — ≥20 AmpicillinC,n AMP 10 μg EnterobacteriaceaeE and Vibrio choleraef ≤13 14-16 ≥17 Staphylococcus spp.A,Q ≤28 — ≥29 Enterococcus spp.A,V,W,k,m ≤16 — ≥17 Haemophilus spp.Y ≤18 19-21 ≥22 Streptococcus spp. ß-Hemolytic GroupA,d — — ≥24 Ampicillin – Sulbactam SAM 10/10 μg EnterobacteriaceaeE, Acinetobacter spp., and Staphylococcus spp. ≤11 12-14 ≥15 Haemophilus spp.A,Y ≤19 — ≥20 Azithromycin AZM 15 μg Staphylococcus spp., Streptococcus spp Viridans Groupn, ß-Hemolytic Group, and S. pneumoniae) ≤13 14-17 ≥18 Neisseria meningitidisA,i — — ≥20 Haemophilus spp.A — — ≥12 Aztreonam ATM 30 μg EnterobacteriaceaeE ≤17 18-20 ≤21 P. aeruginosa ≤15 16-21 ≥22 Haemophilus spp.A — — ≥26 CAR 100 μg Carbenicillin Enterobacteriaceae ≤19 20-22 ≥23 Pseudomonas aeruginosaP ≤13 14-16 ≥17 CEC 30 μg Cefaclor Enterobacteriaceae and Staphylococcus spp. ≤14 15-17 ≥18 Haemophilus spp.Y ≤16 17-19 ≥20 MA 30 μg Cefamandole EnterobacteriaceaeD,E and Staphylococcus spp. ≤14 15-17 ≥18 CefazolinG KZ 30 μg Staphylococcus spp.
  • GERONTOLOGICAL NURSE PRACTITIONER Review and Resource M Anual

    GERONTOLOGICAL NURSE PRACTITIONER Review and Resource M Anual

    13 Male Reproductive System Disorders Vaunette Fay, PhD, RN, FNP-BC, GNP-BC GERIATRIC APPRoACH Normal Changes of Aging Male Reproductive System • Decreased testosterone level leads to increased estrogen-to-androgen ratio • Testicular atrophy • Decreased sperm motility; fertility reduced but extant • Increased incidence of gynecomastia Sexual function • Slowed arousal—increased time to achieve erection • Erection less firm, shorter lasting • Delayed ejaculation and decreased forcefulness at ejaculation • Longer interval to achieving subsequent erection Prostate • By fourth decade of life, stromal fibrous elements and glandular tissue hypertrophy, stimulated by dihydrotestosterone (DHT, the active androgen within the prostate); hyperplastic nodules enlarge in size, ultimately leading to urethral obstruction 398 GERONTOLOGICAL NURSE PRACTITIONER Review and Resource M anual Clinical Implications History • Many men are overly sensitive about complaints of the male genitourinary system; men are often not inclined to initiate discussion, seek help; important to take active role in screening with an approach that is open, trustworthy, and nonjudgmental • Sexual function remains important to many men, even at ages over 80 • Lack of an available partner, poor health, erectile dysfunction, medication adverse effects, and lack of desire are the main reasons men do not continue to have sex • Acute and chronic alcohol use can lead to impotence in men • Nocturia is reported in 66% of patients over 65 – Due to impaired ability to concentrate urine, reduced
  • Mechanisms of Resistance to P-Lactam Antibiotics Amongst 1993

    Mechanisms of Resistance to P-Lactam Antibiotics Amongst 1993

    J. Med. Microbiol. - Vol. 43 (1999, 30G309 0 1995 The Pathological Society of Great Britain and Ireland ANTI MICROBIAL AGENTS Mechanisms of resistance to p-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993 H. Y. CHEN, ME1 YUAN and D. M. LIVERMORE Department of Medical Microbiology, The London Hospital Medical College, Turner Street, London El 2AD Summary. Antimicrobial resistance among 199 1 Pseudomonas aeruginosa isolates collected at 24 UK hospitals during late 1993 was surveyed. Three-hundred and seventy-two of the isolates were resistant, or had reduced susceptibility, to some or all of azlocillin, carbenicillin, ceftazidime, imipenem and meropenem, and the mechanisms underlying their behaviour were examined. Only 13 isolates produced secondary p-lactamases : six possessed PSE- 1 or PSE-4 enzymes and seven had novel OXA enzyme types. Those with PSE types were highly resistant to azlocillin and carbenicillin whereas those with OXA enzymes were less resistant to these penicillins. Chromosomal p-lactamase derepression was demonstrated in 54 isolates, most of which were resistant to ceftazidime and azlocillin although susceptible to carbenicillin and carbapenems. p-Lactamase-independent “ intrinsic” resistance occurred in 277 isolates and is believed to reflect some combination of impermeability and efflux. Two forms were seen : the classical type, present in 195 isolates, gave carbenicillin resistance (MIC > 128 mg/L) and reduced susceptibility to ciprofloxacin and to all p-lactam agents except imipenem; a novel variant, seen in 82 isolates, affected only azlocillin, ceftazidime and, to a small extent, meropenem. Resistance to imipenem was largely dissociated from that to other p-lactam agents, and probably reflected loss of D2 porin, whereas resistance to meropenem was mostly associated with intrinsic resistance to penicillins and cephalosporins.
  • Medicines to Treat Bacterial Infections

    Medicines to Treat Bacterial Infections

    Government of Western Australia North Metropolitan Health Service Women and Newborn Health Service Medicines to treat bacterial infections This brochure contains some information on Important: Antibiotic resistance can the medicines you may have been prescribed affect us all. to treat a bacterial infection either in hospital or on discharge. Please talk to your doctor or Help limit the development of antibiotic pharmacist if you would like more information resistance by using antibiotics correctly. on a specific antibiotic. Make sure you: Take antibiotics exactly as prescribed. What is an antibiotic? • Antibiotics are medicines used to treat • Follow instructions on how many times a infections caused by bacteria. They are not day and for how long to take them. effective against viral infections such as the • Do not stop treatment early, even if you common cold and the ‘flu’. feel better. Medicine Other information Amoxicillin May be taken with or without food. Amoxicillin/ Take with the first bite of a meal. clavulanic acid Cefalexin May be taken with or without food. Take on an empty stomach with a glass of water, 1 hour before or 2 hours after food. Ciprofloxacin Do not take dairy products, antacids, iron, zinc or calcium within 2 hours of the dose. Clindamycin Take with a full glass of water. May be taken with or without food. Take with food or milk. Remain upright for an hour after dose to prevent damage to the Doxycycline lining of your throat. Do not take dairy products, antacids, iron, zinc or calcium within 2 hours of the dose. Take on an empty stomach, 1 hour before or 2 hours after food.
  • N35.12 Postinfective Urethral Stricture, NEC, Female N35.811 Other

    N35.12 Postinfective Urethral Stricture, NEC, Female N35.811 Other

    N35.12 Postinfective urethral stricture, NEC, female N35.811 Other urethral stricture, male, meatal N35.812 Other urethral bulbous stricture, male N35.813 Other membranous urethral stricture, male N35.814 Other anterior urethral stricture, male, anterior N35.816 Other urethral stricture, male, overlapping sites N35.819 Other urethral stricture, male, unspecified site N35.82 Other urethral stricture, female N35.911 Unspecified urethral stricture, male, meatal N35.912 Unspecified bulbous urethral stricture, male N35.913 Unspecified membranous urethral stricture, male N35.914 Unspecified anterior urethral stricture, male N35.916 Unspecified urethral stricture, male, overlapping sites N35.919 Unspecified urethral stricture, male, unspecified site N35.92 Unspecified urethral stricture, female N36.0 Urethral fistula N36.1 Urethral diverticulum N36.2 Urethral caruncle N36.41 Hypermobility of urethra N36.42 Intrinsic sphincter deficiency (ISD) N36.43 Combined hypermobility of urethra and intrns sphincter defic N36.44 Muscular disorders of urethra N36.5 Urethral false passage N36.8 Other specified disorders of urethra N36.9 Urethral disorder, unspecified N37 Urethral disorders in diseases classified elsewhere N39.0 Urinary tract infection, site not specified N39.3 Stress incontinence (female) (male) N39.41 Urge incontinence N39.42 Incontinence without sensory awareness N39.43 Post-void dribbling N39.44 Nocturnal enuresis N39.45 Continuous leakage N39.46 Mixed incontinence N39.490 Overflow incontinence N39.491 Coital incontinence N39.492 Postural
  • Final Decisions & Reasons for Decisions by Delegates of the Secretary to the Department of Health

    Final Decisions & Reasons for Decisions by Delegates of the Secretary to the Department of Health

    Final decisions & reasons for decisions by delegates of the Secretary to the Department of Health 29 June 2017 (ACMS and ACCS meetings – March 2017) Notice under subsections 42ZCZS/42ZCZX of the Therapeutic Goods Regulations 1990 (the Regulations) The delegates of the Secretary to the Department of Health hereby give notice of delegates’ final decisions for amending the Poisons Standard (commonly referred to as the Standard for the Uniform Scheduling of Medicines and Poisons - SUSMP) under subsections 42ZCZS/42ZCZX of the Therapeutic Goods Regulations 1990 (the Regulations). This notice also provides the reasons for each decision and the date of effect (implementation date) of the decision. The delegates’ final decisions and reasons relate to: · scheduling proposals initially referred to the March 2017 meeting of the Advisory Committee on Medicines Scheduling (ACMS#20); · scheduling proposals initially referred to the March 2017 Joint meeting of the Advisory Committees on Chemicals and Medicines Scheduling (ACCS-ACMS#15); · scheduling proposals initially referred to the March 2017 meeting of the Advisory Committee on Chemicals Scheduling (ACCS#19); and · scheduling proposals considered as delegate-only matters, i.e. not referred to an expert advisory committee. Scheduling proposals referred to the expert advisory committees. Pre-meeting public notices On 22 December 2016 and 3 February 2017, under subsection 42ZCZK of the Therapeutic Goods Regulations 1990 (the Regulations), the delegate published pre-meeting public notices on the TGA website which specified the proposed amendments to the current Poisons Standard. The notices also invited public comment on the scheduling proposals referred to the expert advisory committees. The pre-meeting consultation periods were open for public comment for 20 business days and closed on 10 February 2017 and 3 March 2017, respectively.